SCHEDULE 13G: T. Rowe Price Discloses 6.4% Stake in VAXCYTE INC
Beneficial Ownership Report
T. Rowe Price Investment Management, Inc. has reported a 6.4% beneficial ownership stake in VAXCYTE INC, holding over 8.3 million shares of common stock.
Summary
- T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, disclosing its beneficial ownership in VAXCYTE INC.
- The firm beneficially owns an aggregate of 8,315,476 shares of VAXCYTE INC common stock.
- This ownership represents 6.4% of the total class of VAXCYTE INC's common stock.
- T. Rowe Price holds sole voting power over 8,136,062 shares and sole dispositive power over all 8,315,476 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of VAXCYTE INC.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of ownership. The slightly positive sentiment stems from the fact that a reputable institutional investor like T. Rowe Price has taken a significant stake (6.4%) in VAXCYTE INC, which can be interpreted by the market as a vote of confidence, although the filing explicitly states it is not for control purposes.
Positives
- A significant institutional investor like T. Rowe Price taking a 6.4% stake can be viewed positively by the market, indicating confidence in VAXCYTE INC's long-term prospects.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment by T. Rowe Price, a major global asset manager, in VAXCYTE INC, a publicly traded company. Such disclosures are common as large investment firms manage diversified portfolios and cross statutory ownership thresholds, signaling their positions in various companies.
Stakeholder Impact
- Shareholders: May view the significant institutional investment as a positive signal, potentially increasing investor confidence and demand for the stock.
- Management: The presence of a large institutional investor may lead to increased scrutiny or engagement, though the filing states the investment is not for control purposes.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of the event which required the filing of this statement, when T. Rowe Price's beneficial ownership crossed the reporting threshold. |
| 11/14/2025 | Date the Schedule 13G statement was signed by T. Rowe Price Investment Management, Inc. |
Keywords
VAXCYTE INC, T. Rowe Price, beneficial ownership, Schedule 13G, investment management, common stock, institutional investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.